2017
DOI: 10.1177/1010428317705749
|View full text |Cite
|
Sign up to set email alerts
|

Future perspectives of circulating tumor DNA in colorectal cancer

Abstract: Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
14
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 18 publications
(15 citation statements)
references
References 116 publications
1
14
0
Order By: Relevance
“…An Alu-based quantitative-PCR could differentiate tumors from adenomas, based on evaluation of cfDNA levels [97]. Aberrant patterns of methylation have been described in the cfDNA [98]. The methylation status of the Septin 9 gene promoter has been used for the diagnosis of early CRC, and the reported sensitivity and specificity is 30–75%, and 90%, respectively [99].…”
Section: Blood Biomarkersmentioning
confidence: 99%
“…An Alu-based quantitative-PCR could differentiate tumors from adenomas, based on evaluation of cfDNA levels [97]. Aberrant patterns of methylation have been described in the cfDNA [98]. The methylation status of the Septin 9 gene promoter has been used for the diagnosis of early CRC, and the reported sensitivity and specificity is 30–75%, and 90%, respectively [99].…”
Section: Blood Biomarkersmentioning
confidence: 99%
“…However, when the first response to treatment evaluation was performed, in one patient ddPCR values become zero with a clear increase of CEA and without a significant decrease in CA19-9 measurements, and in several patients the reduction in ddPCR values was more pronounced when compared to these classic serum tumor markers. These differences may at least partially depend on the short half-life of ctDNA in the blood when compared to the protein tumor markers [15].…”
Section: Plos Onementioning
confidence: 99%
“…90 However, the desirability of using cfDNA as a biomarker lies in its non-invasive nature and accessibility, and a combined use with previously established tumor markers (Table 2) could be the first step toward the clinical approach to improve cancer diagnosis, treatment, and minimal residual disease monitoring. 117 Furthermore, technological advances via NGS have already revolutionized the field of cancer genomics by facilitating the detection of cancer-specific alterations in KRAS, EGFR, BRAF, and PIK3CA in plasma samples of lung, breast, and colorectal cancer patients as a new and developing area of research. 114 Although biomarker discovery is a budding field, several other tumor entities still lack frequent genetic changes, accentuating the necessity for the discovery of cancer-specific signatures in improving the analytical and diagnostic sensitivity of cancer.…”
Section: Resultsmentioning
confidence: 99%